南昌大学学报(医学版)
南昌大學學報(醫學版)
남창대학학보(의학판)
ACTA ACADEMIAE MEDICINAE JIANGXI
2015年
1期
33-36,47
,共5页
类风湿关节炎%甲氨蝶呤%艾拉莫德
類風濕關節炎%甲氨蝶呤%艾拉莫德
류풍습관절염%갑안접령%애랍막덕
methotrexate%iguratimod%rheumatoid arthritis
目的:观察甲氨蝶呤(MTX)联合艾拉莫德治疗活动期类风湿关节炎(RA)的疗效和安全性。方法选取符合美国风湿病学会(ACR)和欧洲抗风湿联盟(EULAR)2010年联合推出的 RA 诊断标准的活动期 RA 患者60例,按随机数字表法分为研究组和对照组,每组30例。研究组采用 MTX+艾拉莫德治疗,对照组单用 MTX 治疗。记录治疗前及治疗24周后2组关节压痛计数、关节肿胀计数、疼痛指数(VAS 评分)、患者对病情的总体评估(VAS评分)、医生对病情的总体评估(VAS 评分)、RA 疾病活动性评分(DAS28)、健康评估问卷(HAQ)、简明疾病活动指数(SDAI)及血常规、尿常规、肝肾功能、血沉(ESR)、C 反应蛋白(CRP),并评估2组 ACR 缓解率和安全性。结果治疗24周后,研究组 ACR50、DAS28、ESR、CRP、HAQ、SDAI、关节肿胀计数、关节压痛计数、疼痛指数、患者对病情总体评估、医生对病情总体评估均优于对照组(P <0.05);研究组不良事件与对照组相比未见明显增多(P >0.05)。结论MTX 联合艾拉莫德治疗活动期 RA 较单用甲氨蝶呤临床疗效好,且不良事件小,安全性好。
目的:觀察甲氨蝶呤(MTX)聯閤艾拉莫德治療活動期類風濕關節炎(RA)的療效和安全性。方法選取符閤美國風濕病學會(ACR)和歐洲抗風濕聯盟(EULAR)2010年聯閤推齣的 RA 診斷標準的活動期 RA 患者60例,按隨機數字錶法分為研究組和對照組,每組30例。研究組採用 MTX+艾拉莫德治療,對照組單用 MTX 治療。記錄治療前及治療24週後2組關節壓痛計數、關節腫脹計數、疼痛指數(VAS 評分)、患者對病情的總體評估(VAS評分)、醫生對病情的總體評估(VAS 評分)、RA 疾病活動性評分(DAS28)、健康評估問捲(HAQ)、簡明疾病活動指數(SDAI)及血常規、尿常規、肝腎功能、血沉(ESR)、C 反應蛋白(CRP),併評估2組 ACR 緩解率和安全性。結果治療24週後,研究組 ACR50、DAS28、ESR、CRP、HAQ、SDAI、關節腫脹計數、關節壓痛計數、疼痛指數、患者對病情總體評估、醫生對病情總體評估均優于對照組(P <0.05);研究組不良事件與對照組相比未見明顯增多(P >0.05)。結論MTX 聯閤艾拉莫德治療活動期 RA 較單用甲氨蝶呤臨床療效好,且不良事件小,安全性好。
목적:관찰갑안접령(MTX)연합애랍막덕치료활동기류풍습관절염(RA)적료효화안전성。방법선취부합미국풍습병학회(ACR)화구주항풍습련맹(EULAR)2010년연합추출적 RA 진단표준적활동기 RA 환자60례,안수궤수자표법분위연구조화대조조,매조30례。연구조채용 MTX+애랍막덕치료,대조조단용 MTX 치료。기록치료전급치료24주후2조관절압통계수、관절종창계수、동통지수(VAS 평분)、환자대병정적총체평고(VAS평분)、의생대병정적총체평고(VAS 평분)、RA 질병활동성평분(DAS28)、건강평고문권(HAQ)、간명질병활동지수(SDAI)급혈상규、뇨상규、간신공능、혈침(ESR)、C 반응단백(CRP),병평고2조 ACR 완해솔화안전성。결과치료24주후,연구조 ACR50、DAS28、ESR、CRP、HAQ、SDAI、관절종창계수、관절압통계수、동통지수、환자대병정총체평고、의생대병정총체평고균우우대조조(P <0.05);연구조불량사건여대조조상비미견명현증다(P >0.05)。결론MTX 연합애랍막덕치료활동기 RA 교단용갑안접령림상료효호,차불량사건소,안전성호。
Objective To observe the efficacy and safety of methotrexate(MTX)combined with iguratimod in the treatment of active rheumatoid arthritis(RA).Methods Sixty RA patients were enrolled according to the 2010 American College of Rheumatology (ACR)and the European League Against Rheumatism (EULAR)classification criteria,and were randomly treated with MTX alone(control group,n=30)or in combination with iguratimod(combined group,n=30). The counts of joint tenderness and swelling,VAS scores for pain index and patients’and physi-cians’global assessment,disease activity score of RA(DAS28),questionnaires for health assess-ment(HAQ),simplified disease activity index(SDAI),routine blood parameters,routine urine pa-rameters,hepatic and renal function,erythrocyte sedimentation rate(ESR),and C-reactive protein (CRP)levels were recorded before and after treatment for 24 weeks.In addition,the ACR remis-sion rate and safety were evaluated in both groups.Results Compared with control group,the ACR50,DAS28,ESR,CRP,HAQ、SDAI、counts of joint tenderness and swelling、pain index、pa-tients'and physicians'global assessment,and other improved in combined group(P <0.05).No sig-nificant differences in adverse reactions were found between the two groups(P >0.05).Conclusion Combined treatment with MTX and iguratimod is superior to MTX alone for treating active RA with less adverse reactions and higher safety.